- Home
- ELUT
ELUT
Elutia Inc.
as of 12-10-2025 4:00pm EST
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 25.2M | IPO Year: | 2020 |
| Target Price: | $7.00 | AVG Volume (30 days): | 252.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.58 - $4.84 | Next Earning Date: | 11-06-2025 |
| Revenue: | $21,746,000 | Revenue Growth: | 24.08% |
| Revenue Growth (this year): | -16.52% | Revenue Growth (next year): | -30.58% |
AI-Powered ELUT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Elutia Inc. (ELUT)
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$0.67
Shares
5,500
Total Value
$3,685.00
Owned After
379,071
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$0.65
Shares
4,500
Total Value
$2,925.00
Owned After
379,071
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$0.60
Shares
5,000
Total Value
$3,000.00
Owned After
358,785
SEC Form 4
Director
Avg Cost/Share
$0.74
Shares
15,500
Total Value
$11,470.00
Owned After
18,598
SEC Form 4
PRESIDENT AND CEO
Avg Cost/Share
$0.75
Shares
13,500
Total Value
$10,110.00
Owned After
358,785
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ferguson Matthew | ELUT | CHIEF FINANCIAL OFFICER | Dec 2, 2025 | Buy | $0.67 | 5,500 | $3,685.00 | 379,071 | |
| Ferguson Matthew | ELUT | CHIEF FINANCIAL OFFICER | Dec 1, 2025 | Buy | $0.65 | 4,500 | $2,925.00 | 379,071 | |
| Mills C Randal | ELUT | PRESIDENT AND CEO | Nov 24, 2025 | Buy | $0.60 | 5,000 | $3,000.00 | 358,785 | |
| Colpman David | ELUT | Director | Nov 17, 2025 | Buy | $0.74 | 15,500 | $11,470.00 | 18,598 | |
| Mills C Randal | ELUT | PRESIDENT AND CEO | Nov 13, 2025 | Buy | $0.75 | 13,500 | $10,110.00 | 358,785 |
Compare ELUT vs Leading Stocks
See how ELUT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ELUT Elutia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.